Tag:

Amyvid

Latest Headlines

Latest Headlines

Lilly fails to persuade Medicare to pay for Alzheimer's imaging drug

The Centers for Medicare & Medicaid Services' final decision on Eli Lilly's Alzheimer's imaging agent Amyvid, after appeals from Lilly and patient groups, is that Medicare won't pay for Amyvid-aided brain scans outside of clinical trials.

Alzheimer's group pledges fight for Lilly's Amyvid

Eli Lilly has some allies for a brewing fight with Medicare. Alzheimer's groups are ready to back Amyvid, the company's imaging agent, in hopes that the Centers for Medicare and Medicaid Services will decide to pay for a diagnostic test after all.

Medicare won't pay for Eli Lilly Alzheimer's agent

Medicare has put up a big roadblock to Eli Lilly's Alzheimer's screening product Amyvid. The Centers for Medicare & Medicaid Services says it will only pay for the diagnostic agent if patients using it are in clinical trials, at least for now.

EU signs off on Lilly's Alzheimer's imaging agent

While Eli Lilly struggles with development of its therapy for treating Alzheimer's disease, its diagnostic imaging agent for helping diagnose, or rule out, the condition has gotten another approval, this time in Europe.

EU signs off on Lilly's Amyvid, its diagnostic test for Alzheimer's

While Eli Lilly struggles with development of its therapy for treating Alzheimer's disease, its diagnostic imaging agent for helping diagnose, or rule out, the condition has gotten another approval, this time in Europe.

Lilly on verge of EU approval for brain plaque diagnostic tool

Eli Lilly ($LLY) is on the verge of gaining approval in the European Union to use its radioactive diagnostic agent Amyvid as a tool to detect Alzheimer's related brain plaque buildup, 6months after U.S. regulators granted a similar approval.

Piramal lays claim to a late-stage imaging rival for Lilly's Alzheimer's agent

Piramal wasn't saying just how much it paid for the portfolio, but rather breezily claimed that the market for such Alzheimer's imaging agents could amount to $1.5 billion.

FDA approves Lilly's brain plaque diagnostic tool

Eli Lilly ($LLY) failed last year to gain the FDA's approval to use its radioactive diagnostic agent Amyvid for possible Alzheimer's patients. The second time around, it has finally obtained a positive regulatory sign-off, but for a more general indication.

Lilly gains FDA approval for its controversial brain plaque test

Late on Friday, Eli Lilly put out the word that the FDA had approved its brain dye--Amyvid--for use in ruling out Alzheimer's.

Public Citizen: Lilly study excluded key data on Alzheimer's imaging agent

Public Citizen is charging that Eli Lilly purposefully withheld data which demonstrated the unreliability of Amyvid, its experimental new imaging drug for Alzheimer's, when it submitted a study to